2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
47
Carcinoma, Hepatocellular
29
Neoplasms
18
Neoplasm Metastasis
14
Melanoma
14
Stomach Neoplasms
13
Esophageal Neoplasms
13
Colorectal Neoplasms
12
Nasopharyngeal Carcinoma
10
Esophageal Squamous Cell Carcinoma
10
Triple Negative Breast Neoplasms
9
Head and Neck Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Recurrence
8
Breast Neoplasms
8
Rectal Neoplasms
7
Pancreatic Neoplasms
7
Lung Neoplasms
7
Carcinoma, Renal Cell
7
Biliary Tract Neoplasms
7
Small Cell Lung Carcinoma
6
Colonic Neoplasms
5
Cholangiocarcinoma
5
Sarcoma
4
Ovarian Neoplasms
4
Locally Advanced Rectal Cancer
4
Liver Neoplasms
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Interventions
Bevacizumab
7
Paclitaxel
3
vesencumab
2
atezolizumab
2
Immune Checkpoint Inhibitors
2
Carboplatin
2
1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one
2
pertuzumab
1
peginterferon alfa-2a
1
parsatuzumab
1
ovcon 35
1
onartuzumab
1
obinutuzumab
1
ipatasertib
1
emactuzumab
1
Vitamin D
1
Trastuzumab
1
Rosiglitazone
1
Pemetrexed
1
Ipilimumab
1
Interferon alpha-2
1
HhAntag691
1
Grape Seed Extract
1
GDC-0623
1
GDC-0152
1
Docetaxel
1
Cisplatin
1
Capecitabine
1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Solid Cancers
×
Immune Checkpoint Inhibitors
×
Clear all
NCT07427186
2026-02-25
MINER2
Institut Claudius Regaud
Phase NA
Not yet recruiting
600 enrolled
NCT03514368
2026-02-19
MINER
Institut Claudius Regaud
Phase NA
Recruiting
770 enrolled